More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$559343437
EPS
1.21
P/E ratio
12.1
Price to sales
4.97
Dividend yield
--
Beta
1.01622
Previous close
$9.25
Today's open
$9.24
Day's range
$9.04 - $9.41
52 week range
$8.01 - $15.04
show more
CEO
Neil F. Mcfarlane
Employees
61
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
59504621
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 1:00 p.m. ET.
GlobeNewsWire • 11 hours ago

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion
GlobeNewsWire • Nov 13, 2026

Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Nov 9, 2026

Zevra Therapeutics Q3 Earnings Call Highlights
Zevra Therapeutics NASDAQ: ZVRA reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier, driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C, or NPC.
MarketBeat • Nov 3, 2026

Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA
GlobeNewsWire • Nov 3, 2026

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to a loss of $0.01 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call
BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
GlobeNewsWire • Oct 20, 2026

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal
Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA's valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of its rival's acquisition value. Miplyffa's US launch is slow but stable; key risks are insurer restrictions and potential sales declines, with Europe currently valued at zero.
Seeking Alpha • Oct 15, 2026

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond initial estimates.
Seeking Alpha • Oct 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Zevra Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.